The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture.
In the United States, one hepatitis B vaccine (Heptavax-B) has been licensed for the prevention of hepatitis B virus infections. Even though this vaccine has been shown to be highly effective and well tolerated in controlled trials and has been recommended for use in those at risk for acquiring infection by hepatitis B virus, many individuals have been reluctant to be immunized for fear of contracting acquired immunodeficiency syndrome (AIDS). In this study, we demonstrate that each of the three inactivation steps used in the manufacture of Heptavax-B independently will inactivate the infectivity of high-titered preparations of the AIDS virus; recipients of the hepatitis B vaccine do not develop antibodies to the AIDS virus; the hepatitis B vaccine does not contain detectable levels of nucleic acids related to the AIDS virus. These observations clearly demonstrate that vaccination with the currently available hepatitis B vaccine poses no demonstrable risk for acquiring AIDS.
D000914:Antibodies, Viral / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D017977:Deltaretrovirus / Q000235:genetics / Q000276:immunology; D004340:Drug Contamination; D015483:HIV Antibodies; D017325:Hepatitis B Vaccines; D006801:Humans; D009693:Nucleic Acid Hybridization; D012367:RNA, Viral / Q000032:analysis; D012449:Safety; D014613:Vaccines, Attenuated; D014761:Viral Hepatitis Vaccines / Q000032:analysis
D000914:Antibodies, Viral; D004279:DNA, Viral; D015483:HIV Antibodies; D017325:Hepatitis B Vaccines; D012367:RNA, Viral; D014613:Vaccines, Attenuated; D014761:Viral Hepatitis Vaccines